<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">antibiotics</journal-id><journal-title-group><journal-title xml:lang="ru">Антибиотики и Химиотерапия</journal-title><trans-title-group xml:lang="en"><trans-title>Antibiot Khimioter = Antibiotics and Chemotherapy</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0235-2990</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">antibiotics-203</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>В ПОМОЩЬ ПРАКТИКУЮЩЕМУ ВРАЧУ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>GUIDELINES FOR PRACTITIONERS</subject></subj-group></article-categories><title-group><article-title>Новый противотуберкулёзный препарат Рифапекс</article-title><trans-title-group xml:lang="en"><trans-title>Rifapex, a New Antituberculosis Agent</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Соколова</surname><given-names>Г. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Sokolova</surname><given-names>G. B.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Краснов</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Krasnov</surname><given-names>V. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рейхруд</surname><given-names>Т. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Reikhrud</surname><given-names>T. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Цыбанев</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Tsybanev</surname><given-names>A. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Московской медицинской академии им. И.М. Сеченова, Москва; Новосибирский НИИ туберкулеза</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov Moscow Medical Academy, Moscow; Novosibirsk Research Institute of Tuberculosis</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>13</day><month>05</month><year>2020</year></pub-date><volume>54</volume><issue>1-2</issue><fpage>38</fpage><lpage>41</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Соколова Г.Б., Краснов В.А., Рейхруд Т.А., Цыбанев А.А., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Соколова Г.Б., Краснов В.А., Рейхруд Т.А., Цыбанев А.А.</copyright-holder><copyright-holder xml:lang="en">Sokolova G.B., Krasnov V.A., Reikhrud T.A., Tsybanev A.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.antibiotics-chemotherapy.ru/jour/article/view/203">https://www.antibiotics-chemotherapy.ru/jour/article/view/203</self-uri><abstract><p>Проведена оценка клинико-рентгенологической, бактериологической эффективности и безопасности лечения препаратом рифапексом (рифапентин) в комплексной терапии у 90 больных с впервые выявленным, лекарственно-чувствительным туберкулезом. Показана возможность эффективного использования рифапекса у больных и в острую фазу болезни, и в период долечивания, и при необходимости за короткое время подготовки пациента к операции.</p></abstract><trans-abstract xml:lang="en"><p>Сlinісо-roentgenologlc and bacteriologic efficacy and safety of rifapex (rifapentin) were investigated in the complex therapy of 90 patients with newly recorded drug-susceptible tuberculosis. Pifapex was shown to be effective in the treatment of the patients during the acute phase of the disease, during the treatment completeness and during the short preoperative period.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>лекарственно-чувствительный туберкулез</kwd><kwd>комплексная терапия рифапентин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>drug susceptible tuberculosis</kwd><kwd>complex therapy</kwd><kwd>rifapentin</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Vemon A., Burman W., Benatoret D. et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 1999; 353: 1843-1847</mixed-citation><mixed-citation xml:lang="en">Vemon A., Burman W., Benatoret D. et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 1999; 353: 1843-1847</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">American Thoracic Society, CDC. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149: 1359-1374</mixed-citation><mixed-citation xml:lang="en">American Thoracic Society, CDC. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149: 1359-1374</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
